Tabea Strauß
About Tabea Strauß
Tabea Strauß is a Senior Specialist in Quality Control at Bristol Myers Squibb and a PhD student at the German Center for Neurodegenerative Diseases (DZNE) in Munich, Germany.
Current Position at Bristol Myers Squibb
Tabea Strauß is currently employed as a Senior Specialist in Quality Control at Bristol Myers Squibb. She joined the company in November 2021 and is based in Munich, Bavaria, Germany. Her role involves ensuring the quality and integrity of pharmaceutical products through rigorous control processes.
Current Academic Role at German Center for Neurodegenerative Diseases
Tabea Strauß is also a PhD student at the German Center for Neurodegenerative Diseases (DZNE) in Munich, Bavaria, Germany. This role involves conducting in-depth research in the field of neurodegenerative diseases. Her current academic endeavors complement her professional experience in the pharmaceutical industry.
Previous Positions at German Center for Neurodegenerative Diseases
Before her current role, Tabea Strauß worked at the German Center for Neurodegenerative Diseases (DZNE) from 2016 to 2020. During this period, she was involved in neurodegenerative disease research. Her role allowed her to gain significant insights and expertise in the field of neuroscience.
Internship at NeuroProof GmbH
Tabea Strauß completed an internship at NeuroProof GmbH from 2014 to 2015. During her 3-month internship in Rostock, Mecklenburg-Vorpommern, she was engaged in molecular biology projects. This experience provided her with valuable hands-on experience in molecular biology techniques and methodologies.
Educational Background
Tabea Strauß has an extensive academic background. She studied Chemie und Biochemie and achieved a Bachelor from Ludwig-Maximilians-Universität München from 2010 to 2013. She continued her education at the same university, achieving a Master in Biochemie from 2013 to 2016. She later pursued PhD studies in Neuroscience at the Technical University of Munich, completing her studies between 2016 and 2021.